Search

Your search keyword '"Laganà, Marta"' showing total 190 results
Start Over Author "Laganà, Marta"
190 results on '"Laganà, Marta"'

7. Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy

Author

Pedersini, Rebecca, Laganà, Marta, Bosio, Sara, Zanini, Barbara, Cosentini, Deborah, di Mauro, Pierluigi, Alberti, Andrea, Schivardi, Greta, Laini, Lara, Ippolito, Giuseppe, Amoroso, Vito, Vassalli, Lucia, Simoncini, Edda Lucia, Berruti, Alfredo, and Donato, Francesco

Published
2023
Full Text
View/download PDF

8. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma

Author

Laganà, Marta, Habra, Mouhammed Amir, Remde, Hanna, Almeida, Madson Q., Cosentini, Deborah, Pusceddu, Sara, Grana, Chiara Maria, Corssmit, Eleonora P.M., Bongiovanni, Alberto, De Filpo, Giuseppina, Lim, Eugenie S., Zamparini, Manuel, Grisanti, Salvatore, Deutschbein, Timo, Fassnacht, Martin, Fagundes, Gustavo F.C., Pereira, Maria Adelaide A., Oldani, Simone, Rota, Simone, Prinzi, Natalie, Jimenez, Camilo, and Berruti, Alfredo

Published
2024
Full Text
View/download PDF

10. Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter?

Author

Pedersini, Rebecca, Schivardi, Greta, Laganà, Marta, Laini, Lara, di Mauro, Pierluigi, Zamparini, Manuel, Amoroso, Vito, Bonalumi, Alessia, Bosio, Sara, Zanini, Barbara, Buizza, Chiara, Villa, Nicole, Ravanelli, Marco, Rinaudo, Luca, Grisanti, Salvatore, Farina, Davide, Berruti, Alfredo, Donato, Francesco, and Cosentini, Deborah

Published
2024
Full Text
View/download PDF

14. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis

Author

Laganà, Marta, primary, Balderrama-Brondani, Vania, additional, Herrera, Kelsey Ruth, additional, Chahla, Brenda, additional, Yaylaci, Feyza, additional, Bassett, Roland L, additional, Jimenez, Camilo, additional, Varghese, Jeena, additional, Waguespack, Steven G, additional, Campbell, Matthew T, additional, Shah, Amishi Y, additional, Rojas Hernandez, Cristhiam M, additional, and Habra, Mouhammed Amir, additional

Published
2024
Full Text
View/download PDF

15. CXCR4 Antagonist in HPV5-Associated Perianal Squamous-Cell Carcinoma

Author

Marin-Esteban, Viviana, primary, Molet, Lucie, additional, Laganà, Marta, additional, Ciocan, Dragos, additional, Dominguez-Lafage, Clément, additional, Alouche, Nagham, additional, Nguyen, Julie, additional, Gallego, Carmen, additional, Mercier-Nomé, Françoise, additional, Jaracz-Ros, Agnieszka, additional, Beaupain, Blandine, additional, Bouligand, Jérôme, additional, Proust, Alexis, additional, Habib, Christophe, additional, Bonnin, Rémy A., additional, Girlich, Delphine, additional, Fouyssac, Fanny, additional, Schmutz, Jean-Luc, additional, Bursztejn, Anne-Claire, additional, Bellanné-Chantelot, Christine, additional, Bourrat, Emmanuelle, additional, Herfs, Michael, additional, Espéli, Marion, additional, Balabanian, Karl, additional, Schlecht-Louf, Géraldine, additional, Donadieu, Jean, additional, Bachelerie, Françoise, additional, and Deback, Claire, additional

Published
2024
Full Text
View/download PDF

20. Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report.

Author

Fassi, Elena, Amoroso, Vito, Cosentini, Deborah, Ferrari, Vittorio, Laganà, Marta, Berruti, Alfredo, and di Mauro, Pierluigi

Subjects
SARS-CoV-2, BLOOD cell count, PROTEIN-tyrosine kinase inhibitors, DISEASE relapse, SUNITINIB, GASTROINTESTINAL stromal tumors
Abstract

Introduction: Regorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) indicated for the treatment of various tumor types, including metastatic gastrointestinal stromal tumors (GIST), as a third-line systemic therapy. Erythrocytosis, which is characterized by an increase in erythrocyte count, hemoglobin, and hematocrit levels, has been described as a side effect of some antiangiogenic TKIs but has never been associatedwith regorafenib administration. Case presentation: An extra-GIST was diagnosed in a 58-year-old woman after she underwent surgery to remove a pelvic mass. Three years later, systemic therapy with imatinib was started due to pelvic disease recurrence. However, after six months, due to disease progression, we prescribed sunitinib, which the patient received for four years. Regorafenib was initiated in June 2019, and after six months, we noted an increase in the erythrocytes' count and hemoglobin (Hb) levels. Given that the patient had clinical benefit and hematocrit was within normal range, we only monitored the blood cell count and continued to give regorafenib at the same dose. The drug was then stopped for over six weeks due to hospitalization for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection, and Hb levels returned to normal. Therefore, we decided to restart regorafenib at a lower dose. However, Hb levels rose again in conjunction with increased hematocrit, resulting in the need for multiple phlebotomies. We attempted to restart regorafenib every other day, but it was unsuccessful, so we stopped it permanently in May 2023, and all values returned to normal. Conclusion: Regorafenib may cause secondary erythrocytosis that could not be dose-related, as this case report suggests. Secondary erythrocytosis might be a marker of TKI efficacy, given the patient's prolonged clinical benefit during regorafenib treatment (48 months). In patients receiving regorafenib, monitoring blood count as well as any symptoms associated with erythrocytosis may be suggested. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies.

Author

Birtolo, Maria Francesca, Pedersini, Rebecca, Palermo, Andrea, Vena, Walter, Morenghi, Emanuela, Cristofolini, Giacomo, Presciuttini, Barbara, Tabacco, Gaia, Naciu, Anda Mihaela, Pigni, Stella, Laganà, Marta, Mazzoleni, Federica, Cosentini, Deborah, Ciafardini, Antea, Pagani, Mauro, Farina, Davide, Balzarini, Luca, Zambelli, Alberto, Torrisi, Rosalba, and Cianferotti, Luisella

Subjects
VERTEBRAL fractures, BONE health, BONE density, HIP fractures, BONE fractures
Abstract

Background Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown. Methods This retrospective multicenter study included 306 premenopausal women with early BC undergoing HDTs. Bone mineral density (BMD) and morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation and then after at least 24 months. Results After initial assessment, bone-active drugs were prescribed in 77.5% of women (151 denosumab 60 mg/6 months, 86 bisphosphonates). After 47.0 ± 20.1 months, new VFs were found in 16 women (5.2%). Vertebral fracture risk was significantly associated with obesity (odds ratio [OR] 3.87, P =.028), family history of hip fractures or VFs (OR 3.21, P =.040], chemotherapy-induced menopause (OR 6.48, P <.001), preexisting VFs (OR 25.36, P <.001), baseline T -score less than or equal to −2.5 standard deviation (SD) at any skeletal site (OR 4.14, P =.036), and changes at lumbar and total hip BMD (OR 0.94, P =.038 and OR 0.88, P <.001, respectively). New VFs occurred more frequently in women untreated compared to those treated with bone-active drugs (14/69, 20.8% vs 2/237, 0.8%; P <.001) and the anti-fracture effectiveness remained significant after correction for BMI (OR 0.03; P <.001), family history of fractures (OR 0.03; P <.001), chemotherapy-induced menopause (OR 0.04; P <.001), and preexisting VFs (OR 0.01; P <.001). Conclusions Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. The Value of Local Therapies in Advanced Adrenocortical Carcinoma

Author

Kimpel, Otilia, primary, Altieri, Barbara, additional, Laganà, Marta, additional, Vogl, Thomas J., additional, Adwan, Hamzah, additional, Dusek, Tina, additional, Basile, Vittoria, additional, Pittaway, James, additional, Dischinger, Ulrich, additional, Quinkler, Marcus, additional, Kroiss, Matthias, additional, Puglisi, Soraya, additional, Cosentini, Deborah, additional, Kickuth, Ralph, additional, Kastelan, Darko, additional, and Fassnacht, Martin, additional

Published
2024
Full Text
View/download PDF

23. Oncological treatment administration at end of life: a retrospective study

Author

Gurizzan, Cristina, primary, Esposito, Andrea, additional, Lorini, Luigi, additional, Smussi, Davide, additional, Turla, Antonella, additional, Baggi, Alice, additional, Laganà, Marta, additional, Zamparini, Manuel, additional, Bianchi, Susanna, additional, Volta, Alberto Dalla, additional, Grisanti, Salvatore, additional, Giacomelli, Luca, additional, Berruti, Alfredo, additional, and Bossi, Paolo, additional

Published
2024
Full Text
View/download PDF

27. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.

Author

Bergamini, Marco, Volta, Alberto Dalla, Palumbo, Carlotta, Zamboni, Stefania, Triggiani, Luca, Zamparini, Manuel, Laganà, Marta, Rinaudo, Luca, Di Meo, Nunzia, Caramella, Irene, Bresciani, Roberto, Valcamonico, Francesca, Borghetti, Paolo, Guerini, Andrea, Farina, Davide, Antonelli, Alessandro, Simeone, Claudio, Mazziotti, Gherardo, and Berruti, Alfredo

Published
2024
Full Text
View/download PDF

29. THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma

Author

Terzolo, Massimo, primary, Grisanti, Salvatore, additional, Scatolini, Maria, additional, Tomaiuolo, Pasquale, additional, Grosso, Enrico, additional, Basile, Vittoria, additional, Cosentini, Deborah, additional, Puglisi, Soraya, additional, Laganà, Marta, additional, Perotti, Paola, additional, Saba, Laura, additional, Rossini, Elisa, additional, Sigala, Sandra, additional, Volante, Marco, additional, and Berruti, Alfredo, additional

Published
2023
Full Text
View/download PDF

30. Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status

Author

Turla, Antonella, primary, Laganà, Marta, additional, Abate, Andrea, additional, Cremaschi, Valentina, additional, Zamparini, Manuel, additional, Chittò, Matteo, additional, Consoli, Francesca, additional, Alberti, Andrea, additional, Ambrosini, Roberta, additional, Tamburello, Mariangela, additional, Grisanti, Salvatore, additional, Tiberio, Guido Alberto Massimo, additional, Sigala, Sandra, additional, Cosentini, Deborah, additional, and Berruti, Alfredo, additional

Published
2023
Full Text
View/download PDF

32. Reprogramming of connexin landscape fosters fast gap junction intercellular communication in human papillomavirus-infected epithelia

Author

Gallego, Carmen, primary, Jaracz-Ros, Agnieszka, additional, Laganà, Marta, additional, Mercier-Nomé, Françoise, additional, Domenichini, Séverine, additional, Fumagalli, Amos, additional, Roingeard, Philippe, additional, Herfs, Michael, additional, Pidoux, Guillaume, additional, Bachelerie, Françoise, additional, and Schlecht-Louf, Géraldine, additional

Published
2023
Full Text
View/download PDF

33. Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines

Author

Tamburello, Mariangela, primary, Abate, Andrea, additional, Rossini, Elisa, additional, Basnet, Ram Manohar, additional, Zizioli, Daniela, additional, Cosentini, Deborah, additional, Hantel, Constanze, additional, Laganà, Marta, additional, Tiberio, Guido Alberto Massimo, additional, Grisanti, Salvatore, additional, Memo, Maurizio, additional, Berruti, Alfredo, additional, and Sigala, Sandra, additional

Published
2023
Full Text
View/download PDF

34. New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study

Author

Puglisi, Soraya, primary, Calabrese, Anna, additional, Ferraù, Francesco, additional, Violi, Maria Antonia, additional, Laganà, Marta, additional, Grisanti, Salvatore, additional, Ceccato, Filippo, additional, Scaroni, Carla, additional, Di Dalmazi, Guido, additional, Stigliano, Antonio, additional, Altieri, Barbara, additional, Canu, Letizia, additional, Loli, Paola, additional, Pivonello, Rosario, additional, Arvat, Emanuela, additional, Morelli, Valentina, additional, Perotti, Paola, additional, Basile, Vittoria, additional, Berchialla, Paola, additional, Urru, Sara, additional, Fiori, Cristian, additional, Porpiglia, Francesco, additional, Berruti, Alfredo, additional, Pia, Anna, additional, Reimondo, Giuseppe, additional, Cannavò, Salvatore, additional, and Terzolo, Massimo, additional

Published
2023
Full Text
View/download PDF

35. Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines

Author

Tamburello, Mariangela; https://orcid.org/0000-0001-7827-0025, Abate, Andrea; https://orcid.org/0000-0002-0835-0916, Rossini, Elisa; https://orcid.org/0000-0002-4936-8880, Basnet, Ram Manohar, Zizioli, Daniela, Cosentini, Deborah, Hantel, Constanze, Laganà, Marta, Tiberio, Guido Alberto Massimo; https://orcid.org/0000-0002-7635-1179, Grisanti, Salvatore; https://orcid.org/0000-0001-6922-1934, Memo, Maurizio; https://orcid.org/0000-0002-7543-0289, Berruti, Alfredo; https://orcid.org/0000-0002-2952-9560, Sigala, Sandra; https://orcid.org/0000-0003-3294-4121, Tamburello, Mariangela; https://orcid.org/0000-0001-7827-0025, Abate, Andrea; https://orcid.org/0000-0002-0835-0916, Rossini, Elisa; https://orcid.org/0000-0002-4936-8880, Basnet, Ram Manohar, Zizioli, Daniela, Cosentini, Deborah, Hantel, Constanze, Laganà, Marta, Tiberio, Guido Alberto Massimo; https://orcid.org/0000-0002-7635-1179, Grisanti, Salvatore; https://orcid.org/0000-0001-6922-1934, Memo, Maurizio; https://orcid.org/0000-0002-7543-0289, Berruti, Alfredo; https://orcid.org/0000-0002-2952-9560, and Sigala, Sandra; https://orcid.org/0000-0003-3294-4121

Abstract

BACKGROUND Adrenocortical cancer (ACC) is a rare malignancy with a dismal prognosis. The treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, and cisplatin). However, new therapeutic approaches for advanced ACC are needed, particularly targeting the metastatic process. Here, we deepen the role of progesterone as a new potential drug for ACC, in line with its antitumoral effect in other cancers. METHODS NCI-H295R, MUC-1, and TVBF-7 cell lines were used and xenografted in zebrafish embryos. Migration and invasion were studied using transwell assays, and MMP2 activity was studied using zymography. Apoptosis and cell cycle were analyzed by flow cytometry. RESULTS Progesterone significantly reduced xenograft tumor area and metastases formation in embryos injected with metastatic lines, MUC-1 and TVBF-7. These results were confirmed in vitro, where the reduction of invasion was mediated, at least in part, by the decrease in MMP2 levels. Progesterone exerted a long-lasting effect in metastatic cells. Progesterone caused apoptosis in NCI-H295R and MUC-1, inducing changes in the cell-cycle distribution, while autophagy was predominantly activated in TVBF-7 cells. CONCLUSION Our results give support to the role of progesterone in ACC. The involvement of its analog (megestrol acetate) in reducing ACC progression in ACC patients undergoing EDP-M therapy is now under investigation in the PESETA phase II clinical study.

Published
2023

36. Le virome cutané : de la virologie à la médecine personnalisée.

Author

Dominguez-Lafage, Clément, Laganà, Marta, Gesbert, Franck, Marin-Esteban, Viviana, Schlecht-Louf, Géraldine, Bachelerie, Françoise, and Deback, Claire

Abstract

The virome of the skin, defined as all viruses detected in the skin, represents a significant part of the microbiota. A much more recent discovery than the bacterial flora, the existence of the cutaneous virome has been revealed by recent metagenomic studies. The normal human skin virome is dominated by bacteriophages, Papillomaviridae , whose genomic diversity has proved extraordinary, and Polyomaviridae. Many yet unknown viral genomes within this virome await identification. The composition of the virome of the skin has been shown to be strictly individual and relatively stable over time, resulting from adaptation to everyone's genetics, lifestyle and mechanisms of immunological tolerance finely selected over the course of evolution. Yet little studied, the virome of the skin and all its interactions with other microbiota and the host are attracting growing interest. Indeed, constitutional or acquired alterations in the homeostasis between the commensal virome and the skin, ranging from sub-clinical viral dysbiosis to severe transformation of keratinocytes or adnexal cells, have been observed. These recent observations are stimulating the search for innovative solutions aimed at measuring or even modulating its pathological expression, with a view to personalized medicine. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report

Author

di Mauro, Pierluigi, primary, Schivardi, Greta, additional, Pedersini, Rebecca, additional, Laini, Lara, additional, Esposito, Andrea, additional, Amoroso, Vito, additional, Laganà, Marta, additional, Grisanti, Salvatore, additional, Cosentini, Deborah, additional, and Berruti, Alfredo, additional

Published
2023
Full Text
View/download PDF

38. Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models

Author

Abate, Andrea, primary, Tamburello, Mariangela, additional, Rossini, Elisa, additional, Basnet, Ram Manohar, additional, Ribaudo, Giovanni, additional, Gianoncelli, Alessandra, additional, Hantel, Constanze, additional, Cosentini, Deborah, additional, Laganà, Marta, additional, Grisanti, Salvatore, additional, Tiberio, Guido Alberto Massimo, additional, Memo, Maurizio, additional, Berruti, Alfredo, additional, and Sigala, Sandra, additional

Published
2023
Full Text
View/download PDF

39. Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines

Author

Tamburello, Mariangela, primary, Abate, Andrea, additional, Rossini, Elisa, additional, Basnet, Ram, additional, Zizioli, Daniela, additional, Cosentini, Deborah, additional, Hantel, Constanze, additional, Laganà, Marta, additional, Tiberio, Guido, additional, Grisanti, Salvatore, additional, Memo, Maurizio, additional, Berruti, Alfredo, additional, and Sigala, Sandra, additional

Published
2022
Full Text
View/download PDF

40. Appendix 1.docx

Author

Puglisi, Soraya, Calabrese, Anna, Ferraù, Francesco, Violi, Maria Antonia, Laganà, Marta, Grisanti, Salvatore, Ceccato, Filippo, Scaroni, Carla, Dalmazi, Guido Di, Stigliano, Antonio, Altieri, Barbara, Canu, Letizia, Loli, Paola, Pivonello, Rosario, Arvat, Emanuela, Morelli, Valentina, Perotti, Paola, Basile, Vittoria, Berchialla, Paola, Urru, Sara, Fiori, Cristian, Porpiglia, Francesco, Berruti, Alfredo, Pia, Anna, Reimondo, Giuseppe, Cannavò, Salvatore, and Terzolo, Massimo

Abstract

Appendix 1

Published
2023
Full Text
View/download PDF

41. OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.

Author

Abate, Andrea, primary, Basile, Vittoria, additional, Berruti, Alfredo, additional, Calabrese, Anna, additional, Cosentini, Deborah, additional, Ferrari, Vittorio Domenico, additional, Grisanti, Salvatore, additional, Laganà, Marta, additional, Perotti, Paola, additional, Pia, Anna, additional, Puglisi, Soraya, additional, Rossini, Elisa, additional, Saba, Laura, additional, Sigala, Sandra, additional, and Terzolo, Massimo, additional

Published
2022
Full Text
View/download PDF

43. Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.

Author

Delbarba, Andrea, Cosentini, Deborah, Facondo, Paolo, Laganà, Marta, Chiara Pezzaioli, Letizia, Cremaschi, Valentina, Alberti, Andrea, Grisanti, Salvatore, Cappelli, Carlo, Ferlin, Alberto, and Berruti, Alfredo

Subjects
LONGITUDINAL method, ANDROGENS, SEX hormones, RETROSPECTIVE studies, CARCINOMA
Abstract

Objective: Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied. This single-center retrospective longitudinal study was undertaken to assess the frequency of testosterone deficiency before and after mitotane therapy, the possible mechanism involved, and the relationship between hypogonadism with serum mitotane levels and prognosis. Research design and methods: Consecutive male ACC patients followed at the Medical Oncology of Spedali Civili Hospital in Brescia underwent hormonal assessment to detect testosterone deficiency at baseline and during mitotane therapy. Results: A total of 24 patients entered the study. Of these patients, 10 (41.7%) already had testosterone deficiency at baseline. During follow-up, total testosterone (TT) showed a biphasic evolution over time with an increase in the first 6 months followed by a subsequent progressive decrease until 36 months. Sex hormone binding globulin (SHBG) progressively increased, and calculated free testosterone (cFT) progressively decreased. Based on cFT evaluation, the proportion of hypogonadic patients progressively increased with a cumulative prevalence of 87.5% over the study course. A negative correlation was observed between serum mitotane levels >14 mg/L and TT and cFT. Conclusion: Testosterone deficiency is common in men with ACC prior to mitotane treatment. In addition, this therapy exposes these patients to further elevated risk of hypogonadism that should be promptly detected and counteracted, since it might have a negative impact on quality of life. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy

Author

Cosentini, Deborah, primary, Grisanti, Salvatore, additional, Hadoux, Julien, additional, Libè, Rossella, additional, Frigerio, Michele, additional, Laganà, Marta, additional, Deschamps, Frederic, additional, Zamparini, Manuel, additional, Lamartina, Livia, additional, Pedersini, Rebecca, additional, Valsecchi, Clara, additional, Maroldi, Roberto, additional, Al Ghuzlan, Abir, additional, Terzolo, Massimo, additional, Gasparotti, Roberto, additional, Baudin, Eric, additional, and Berruti, Alfredo, additional

Published
2021
Full Text
View/download PDF

46. Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells

Author

Abate, Andrea, primary, Rossini, Elisa, additional, Tamburello, Mariangela, additional, Laganà, Marta, additional, Cosentini, Deborah, additional, Grisanti, Salvatore, additional, Fiorentini, Chiara, additional, Tiberio, Guido A M, additional, Scatolini, Maria, additional, Grosso, Enrico, additional, Hantel, Constanze, additional, Memo, Maurizio, additional, Berruti, Alfredo, additional, and Sigala, Sandra, additional

Published
2021
Full Text
View/download PDF

47. Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic

Author

Gurizzan, Cristina, primary, Pedersini, Rebecca, additional, Fornaro, Carla, additional, Sardini, Chiara, additional, Zamparini, Manuel, additional, Monteverdi, Sara, additional, Tovazzi, Valeria, additional, Cosentini, Deborah, additional, Dalla Volta, Alberto, additional, Baggi, Alice, additional, Turla, Antonella, additional, Di Mauro, Pierluigi, additional, Lorini, Luigi, additional, Laganà, Marta, additional, Bianchi, Susanna, additional, Grisanti, Salvatore, additional, Consoli, Francesca, additional, Conti, Elisabetta, additional, Bossi, Paolo, additional, and Berruti, Alfredo, additional

Published
2021
Full Text
View/download PDF

49. The G Protein-Coupled Receptor Kinases (GRKs) in Chemokine Receptor-Mediated Immune Cell Migration: From Molecular Cues to Physiopathology

Author

Laganà, Marta, Schlecht-Louf, Géraldine, and Bachelerie, Françoise

Subjects
G protein-coupled receptor kinases (GRKs), immune cell migration, scaffolding, desensitization, chemokines, Review, atypical chemokine receptors (ACKRs), G-Protein-Coupled Receptor Kinases, lcsh:Biology (General), Cell Movement, G protein-coupled receptors (GPCRs), Animals, Humans, chemoattractant gradients, Receptors, Chemokine, signalling, lcsh:QH301-705.5, Signal Transduction
Abstract

Although G protein-coupled receptor kinases (GRKs) have long been known to regulate G protein-coupled receptor (GPCR) desensitization, their more recently characterized functions as scaffolds and signalling adapters underscore that this small family of proteins governs a larger array of physiological functions than originally suspected. This review explores how GRKs contribute to the complex signalling networks involved in the migration of immune cells along chemokine gradients sensed by cell surface GPCRs. We outline emerging evidence indicating that the coordinated docking of several GRKs on an active chemokine receptor determines a specific receptor phosphorylation barcode that will translate into distinct signalling and migration outcomes. The guidance cues for neutrophil migration are emphasized based on several alterations affecting GRKs or GPCRs reported to be involved in pathological conditions.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results